Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma by Daemen, Anneleen, Cooper, Jonathan E, Myrta, Szymon, Wongchenko, Matthew J, Lin, Eva, Long, Jason E, Foreman, Oded, Modrusan, Zora, Tremayne, Jarrod R, de la Cruz, Cecile C, Merchant, Mark, Martin, Scott E, Yan, Yibing, Junttila, Melissa R

Get full text

Topological Organization Alterations of Whole-Brain Functional Networks in Patients with Childhood Absence Epilepsy: Associations with Treatment Effects by Wang, Xueyu, Fang, Peng, Jiao, Dongmei, Hu, Tian, Yang, Qi, Liang, Wei, Li, Yijun, Yan, Yibing, Liu, Libo

Get full text

Better modulation for risk decision‐making after optimized magnetic stimulation by Wang, Lu, Wu, Xingqi, Ji, Gong‐Jun, Xiao, Guixian, Xu, Feifei, Yan, Yibing, Wu, Yang, Xi, Chunhua, Chen, Xingui, Wang, Kai

Get full text

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM by Lewis, Karl D., Larkin, James, Ribas, Antoni, Flaherty, Keith T., McArthur, Grant A., Ascierto, Paolo A., Dréno, Brigitte, Yan, Yibing, Wongchenko, Matthew, McKenna, Edward, Zhu, Qian, Mun, Yong, Hauschild, Axel

Get full text

Improved Cognitive Promotion through Accelerated Magnetic Stimulation by Wu, Xingqi, Wang, Lu, Geng, Zhi, Wei, Ling, Yan, Yibing, Xie, Chengjuan, Chen, Xingui, Ji, Gong-Jun, Tian, Yanghua, Wang, Kai

Get full text

Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities by Daemen, Anneleen, Cooper, Jonathan E., Myrta, Szymon, Wongchenko, Matthew J., Lin, Eva, Long, Jason E., Foreman, Oded, Modrusan, Zora, Tremayne, Jarrod, de la Cruz, Cecile C., Merchant, Mark, Martin, Scott E., Yan, Yibing, Junttila, Melissa R.

Get full text

Abstract LB-274: Primary tumor gene expression signature predicts long-term outcomes in primary melanoma: A prospective multicenter study by Garg, Manik, Courturier, Dominique-Laurent, Fonseca, Nuno A., Wongchenko, Matthew, Yan, Yibing, Nsengimana, Jeremie, Bishop, Tim, Newton-Bishop, Julia, Middleton, Mark, Corrie, Pippa, Adams, David J., Brazma, Alvis, Rabbie, Roy

Get full text

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAF V600 mutation-positive advanced melanoma: Primary re... by McArthur, Grant A., Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev, Manikhas, Georgy Moiseevich, Yan, Yibing, Huang, K. C., Uyei, Anne, McNally, Virgina, Gutzmer, Ralf, Ascierto, Paolo

Get full text

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised,... by Gutzmer, Ralf, Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo P, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev, Manikhas, Georgy Moiseevich, Yan, Yibing, Huang, Kuan-Chieh, Uyei, Anne, McNally, Virginia, McArthur, Grant A, Ascierto, Paolo A

Get full text

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, d... by Gutzmer, Ralf, Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo P, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev, Manikhas, Georgy Moiseevich, Yan, Yibing, Huang, Kuan-Chieh, Uyei, Anne, McNally, Virginia, McArthur, Grant A, Ascierto, Paolo A

Get full text

Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma by Ribas, Antoni, Daud, Adil, Pavlick, Anna C., Gonzalez, Rene, Lewis, Karl D., Hamid, Omid, Gajewski, Thomas F., Puzanov, Igor, Wongchenko, Matthew, Rooney, Isabelle, Hsu, Jessie J., Yan, Yibing, Park, Erica, McArthur, Grant A.

Get full text

Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial) by Googe, Paul B., Theocharis, Stamatios, Pergaris, Alexandros, Li, Haocheng, Yan, Yibing, McKenna Jr, Edward F., Moschos, Stergios J.

Get full text

ARAF mutations confer resistance to the RAF inhibitobelvarafenib in melanoma by Yen, Ivana, Shanahan, Frances, Lee, Jeeyun, Hong, Yong Sang, Shin, Sang Joon, Moore, Amanda R, Sudhamsu, Jawahar, Chang, Matthew T, Bae, Inhwan, Dela Cruz, Darlene, Hunsaker, Thomas, Klijn, Christiaan, Liau, Nicholas P D, Lin, Eva, Martin, Scott E, Modrusan, Zora, Piskol, Robert, Segal, Ehud, Venkatanarayan, Avinashnarayan, Ye, Xin, Yin, Jianping, Zhang, Liangxuan, Kim, JIN-SOO, Lim, HYEONG-SEOK, Kim, KYU-PYO, Kim, Yu Jung, Han, Hye Sook, Lee, Soo Jung, Kim, Seung Tae, Jung, Minkyu, Hong, Yoon-hee, Noh, Young Su, Choi, Munjeong, Han, Oakpil, Nowicka, Malgorzata, Srinivasan, Shrividhya, Yan, Yibing, Kim, Tae Won, Malek, Shiva

Get full text

bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays by Wang, Kevin Y X, Menzies, Alexander M, Silva, Ines P, Wilmott, James S, Yan, Yibing, Wongchenko, Matthew, Kefford, Richard F, Scolyer, Richard A, Long, Georgina V, Tarr, Garth, Mueller, Samuel, Yang, Jean Y H

Request full text

The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs by Rydenfelt, Mattias, Wongchenko, Matthew, Klinger, Bertram, Yan, Yibing, Blüthgen, Nils

Get full text

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition by Zhou, Wei, Jubb, Adrian M, Lyle, Karen, Xiao, Qian, Ong, Christy C, Desai, Rupal, Fu, Ling, Gnad, Florian, Song, Qinghua, Haverty, Peter M, Aust, Daniela, Grützmann, Robert, Romero, Mally, Totpal, Klara, Neve, Richard M, Yan, Yibing, Forrest, William F, Wang, Yulei, Raja, Rajiv, Pilarsky, Christian, de Jesus-Acosta, Ana, Belvin, Marcia, Friedman, Lori S, Merchant, Mark, Jaffee, Elizabeth M, Zheng, Lei, Koeppen, Hartmut, Hoeflich, Klaus P

Get full text

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma by Yan, Yibing, Wongchenko, Matthew J, Robert, Caroline, Larkin, James, Ascierto, Paolo A, Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B, Sosman, Jeffrey A, Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J, Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A, Ribas, Antoni

Get full text

Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma by Yan, Yibing, Wongchenko, Matthew J., Robert, Caroline, Larkin, James, Ascierto, Paolo A., Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B., Sosman, Jeffrey A., Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J., Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A., Ribas, Antoni

Get full text

Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells by Wong, Matthew J., Wagle, Marie-Claire, Hampton, Garret, Yan, Yibing

Get full text

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combine... by Wongchenko, Matthew J., Ribas, Antoni, Dréno, Brigitte, Ascierto, Paolo A., McArthur, Grant A., Gallo, Jorge D., Rooney, Isabelle A., Hsu, Jessie, Koeppen, Hartmut, Yan, Yibing, Larkin, James

Get full text